OncoMatch/Clinical Trials/NCT06907043
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Is NCT06907043 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies EIK1004-001 (IMP1707-001) for advanced solid tumors.
Treatment: EIK1004-001 (IMP1707-001) — This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced/metastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes. Condition or disease Intervention/treatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1/Phase 2
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: chemotherapy — neoadjuvant/adjuvant/metastatic
Breast cancer: must have received at least one prior chemotherapy in neoadjuvant/adjuvant/metastatic setting
Must have received: hormonal therapy
must have received hormonal therapy if HR+
Must have received: platinum-based chemotherapy — advanced disease
must have received at least one prior platinum-based chemotherapy for advanced disease
Must have received: androgen deprivation therapy — ongoing
mCRPC with ongoing ADT
Must have received: novel hormonal agent
must have received NHA
Must have received: taxane
up to 1 prior line of taxane chemotherapy
Must have received: first-line therapy
Pancreatic cancer, must have prior 1L therapy
Must have received: PARP inhibitor
Up to 1 prior line of PARP inhibitor containing treatment
Cannot have received: PARP1 selective inhibitor
Have received prior PARP1 selective inhibitors
Cannot have received: any investigational or approved anti-cancer therapies
Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of EIK1004 (IMP1707)
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Mean resting QTcF > 470 ms or QTcF < 340 ms [excluded]
Adequate organ function; Mean resting QTcF > 470 ms or QTcF < 340 ms [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarah Cannon Research Institute at HealthOne · Denver, Colorado
- Florida Cancer Center · Lake Mary, Florida
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- MD Anderson · Houston, Texas
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06907043 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior PARP1 selective inhibitor, any investigational or approved anti-cancer therapies disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 89 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify